Question · asked by 1 review
LAMA vs placebo: Pulmonary exacerbations
- Population
- adults and children with cystic fibrosis
- Intervention
- LAMA
- Comparison
- placebo
- Outcome
- Pulmonary exacerbations
LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
LAMAs vs placebo Pulmonary exacerbations: participants reporting ≥1 pulmonary exacerbation during the trial period after tiotropium 5 µg · adults and children with cystic fibrosis LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty). Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane Headline outcomes only | RR 0.6 [0.32, 1.12] | 2 studies · 805 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.